4SC AG: First Patient Enrolled in MERKLIN 2 Study
Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated in Merkel cell carcinoma (MERKLIN 2 study) 4SC AG (4SC, FSE Prime Standard: VSC) today announced that the first patient has been enrolled in the MERKLIN Mehr






